论文部分内容阅读
最近,美国批准使用一种由b型流感杆菌荚膜多糖组成的菌苗。该菌苗的免疫原性和保护效力与年龄显著相关。1岁以内儿童免疫后,抗体应答很差,根据免疫后的抗体应答率和抗荚膜抗体水平,表明1岁以上儿童的抗荚膜抗体应答随免疫年龄的增长而逐渐增高。在芬兰进行的一次试验中,43%的12～17月龄儿童、75%的18～23月龄儿童和90%的24～71月龄儿童免疫接种后,抗体效价超过1.0μg/ml,很多专家认为该抗体浓度
Recently, the United States approved the use of a bacterin consisting of capsid polysaccharide type b. The immunogenicity and protective efficacy of this vaccine are significantly related to age. Antibody responses were poor after immunization of children under 1 year of age. Anti-capsular antibody response in children older than 1 year increased gradually with age of immunization, based on the antibody response rate after immunization and anti-capsular antibody levels. In a trial conducted in Finland, the antibody titer exceeded 1.0 μg / ml after immunization in 43% of children aged 12-17 months, 75% of children aged 18-23 months and 90% of children aged 24-71 months, Many experts believe that the antibody concentration